Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Masimo Corporation - Common Stock (NQ:MASI)

149.01 +4.05 (+2.79%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Masimo Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Masimo’s (NASDAQ:MASI) Q3 Sales Top Estimates
Medical tech company Masimo (NASDAQ:MASI) reported Q3 CY2025 results beating Wall Street’s revenue expectations, with sales up 8.2% year on year to $371.5 million. The company expects the full year’s... 
Via StockStory
Earnings Scheduled For November 4, 2025
 
Via Benzinga
Masimo Earnings Preview
 
Via Benzinga
Earnings To Watch: Masimo (MASI) Reports Q3 Results Tomorrow
Medical tech company Masimo (NASDAQ:MASI) will be reporting results this Tuesday after market hours. Here’s what you need to know. 
Via StockStory
1 Unprofitable Stock with Exciting Potential and 2 We Brush Off
Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure. 
Via StockStory
Topics Electric Vehicles
How Is The Market Feeling About Masimo?
 
Via Benzinga
Apple’s Watch War Heats Up: Masimo Takes Customs To Court Over Blood-Oxygen Feature
Via Stocktwits
Earnings Scheduled For August 5, 2025
 
Via Benzinga
$1000 Invested In Masimo 10 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Recent Report Shows That Rep. Kevin Hern Sold Up to $200K Worth of Accenture Stock
 
Via Benzinga
DexCom, Masimo, Integer Holdings, The Pennant Group, and Organon Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump. 
Via StockStory
Topics Economy Government World Trade
1 Cash-Producing Stock Worth Your Attention and 2 We Brush Off
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
Via StockStory
3 Healthcare Stocks We Think Twice About
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have caused the... 
Via StockStory
Topics Stocks
3 Reasons MASI is Risky and 1 Stock to Buy Instead
Over the past six months, Masimo’s shares (currently trading at $142) have posted a disappointing 17.2% loss, well below the S&P 500’s 18.4% gain. This might have investors contemplating their next... 
Via StockStory
Topics Stocks
Healthcare Sector Navigates Turbulent Waters as Drug Pricing Agreements Reshape Market Landscape
September 30, 2025 – The healthcare sector today finds itself at a pivotal juncture, experiencing a complex mix of optimism and apprehension. While a landmark drug-pricing agreement between... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
Masimo, Integra LifeSciences, CONMED, IQVIA, and Charles River Laboratories Shares Are Soaring, What You Need To Know
A number of stocks jumped in the afternoon session after reports revealed a potential drug-pricing agreement between the White House and the pharmaceutical industry. The Trump administration is... 
Via StockStory
Topics Government World Trade
Here's How Much $100 Invested In Masimo 10 Years Ago Would Be Worth Today
Masimo (NASDAQ: MASI) has outperformed the market over the past 10 years by 1.12% on an annualized basis producing an average annual return of 13.99%. Currently, Masimo has a market capitalization of... 
Via Benzinga
3 of Wall Street’s Favorite Stocks with Questionable Fundamentals
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,... 
Via StockStory
1 Small-Cap Stock Worth Your Attention and 2 Facing Challenges
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside... 
Via StockStory
Consumer Tech News (August 18–August 22): Powell Turns Dovish As Walmart, Target Earnings Steer Sentiment, While AI Hangover Hits Palantir
Powell's dovish Jackson Hole tone, mixed WMT/TGT/TJX earnings, and an AI hangover led by PLTR's slide gave way to a late-week risk rally. 
Via Benzinga
Topics Artificial Intelligence
Sallie Mae, Two Harbors Investment, Flowserve, Masimo, and Select Medical Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after the major indices rebounded, as Fed Chair Jerome Powell delivered dovish remarks at the much-awaited Jackson Hole symposium. Powell suggested... 
Via StockStory
Topics Economy
Apple Restores Blood-Oxygen Tracking To Watch After Customs Ruling — Masimo Strikes Back With Lawsuit Over Patent Rights
Apple reintroduced blood-oxygen tracking on its watches after a Customs ruling, but Masimo has sued to block the feature again. 
Via Benzinga
Topics Intellectual Property Lawsuit
3 Unprofitable Stocks That Fall Short
Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure. 
Via StockStory
Apple To Reintroduce Blood Oxygen Feature On Select Watches Following Customs Ruling
Apple to roll out redesigned Blood Oxygen feature for select U.S. Apple Watch models via software update, following a favorable customs ruling. 
Via Benzinga
Biogen, Moderna, Align Technology, QuidelOrtho, and Masimo Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer... 
Via StockStory
Topics Economy
MASI Q2 Deep Dive: Margin Expansion Amid Tariff Pressures and Strategic Leadership Changes
Medical tech company Masimo (NASDAQ:MASI) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 7.9% year on year to $370.9 million. The company expects the full year’s... 
Via StockStory
Topics World Trade
Q2 Earnings Highlights: Masimo (NASDAQ:MASI) Vs The Rest Of The Patient Monitoring Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how patient monitoring stocks fared in Q2, starting with Masimo... 
Via StockStory
Topics Artificial Intelligence
Masimo’s (NASDAQ:MASI) Q2: Beats On Revenue But Stock Drops
Medical tech company Masimo (NASDAQ:MASI) reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 7.9% year on year to $370.9 million. The company expects the full year’s... 
Via StockStory
Topics World Trade
Masimo (MASI) Reports Q2: Everything You Need To Know Ahead Of Earnings
Medical tech company Masimo (NASDAQ:MASI) will be reporting earnings this Tuesday afternoon. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence Economy World Trade
1 Healthcare Stock to Consider Right Now and 2 That Underwhelm
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Despite the rosy long-term prospects, short-term headwinds such as COVID... 
Via StockStory
Topics Stocks
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.